Biogen (BIIB) Assets (2009 - 2026)
Biogen (BIIB) recorded quarterly Assets of $29.5 billion in Q1 2026, little changed quarter-over-quarter from $29.4 billion in Q4 2025, and up 5.17% on a YoY basis from $28.0 billion in Q1 2025.
Biogen (BIIB) Assets (2009 - 2026) Analysis & Trends
Biogen's Assets history runs 18 years deep, the most recent figure standing at $29.5 billion for Q1 2026.
- In Q1 2026, Assets rose 5.17% year-over-year to $29.5 billion; the TTM figure through Mar 2026 stood at $29.5 billion (up 5.17% YoY), while the FY2025 annual figure was $29.4 billion, up 4.96% from the prior year.
- Assets was $29.5 billion for Q1 2026 at Biogen, roughly flat from $29.4 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $29.5 billion in Q1 2026 to a low of $23.6 billion in Q1 2022.
- Historically, Assets has averaged $26.9 billion across 5 years, with a median of $26.8 billion in 2023.
- The sharpest annual moves came in 2022 and 2023: Assets retreated 1.01% in 2022, then advanced 13.43% in 2023.
- A 5-year view of Assets shows it stood at $24.6 billion in 2022, then climbed by 9.33% to $26.8 billion in 2023, then rose by 4.49% to $28.0 billion in 2024, then rose by 4.96% to $29.4 billion in 2025, then gained by 0.15% to $29.5 billion in 2026.
- The last three Assets figures came in at $29.5 billion (Q1 2026), $29.4 billion (Q4 2025), and $29.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 29.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.48 Bn |
| Dec 31, 2025 | 29.44 Bn |
| Sep 30, 2025 | 29.21 Bn |
| Jun 30, 2025 | 28.33 Bn |
| Mar 31, 2025 | 28.03 Bn |
| Dec 31, 2024 | 28.05 Bn |
| Sep 30, 2024 | 28.31 Bn |
| Jun 30, 2024 | 26.80 Bn |
| Mar 31, 2024 | 26.57 Bn |
| Dec 31, 2023 | 26.84 Bn |
| Sep 30, 2023 | 28.19 Bn |
| Jun 30, 2023 | 25.16 Bn |
| Mar 31, 2023 | 24.60 Bn |
| Dec 31, 2022 | 24.55 Bn |
| Sep 30, 2022 | 24.85 Bn |
| Jun 30, 2022 | 25.08 Bn |
| Mar 31, 2022 | 23.61 Bn |
| Dec 31, 2021 | 23.88 Bn |
| Sep 30, 2021 | 23.81 Bn |
| Jun 30, 2021 | 24.47 Bn |